Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2007

01-12-2007 | Educational Review

Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma—A Strategy to Increase Resectability

Authors: Wan Yee Lau, MD, FACS, FRCS, FRACS(Hon), Eric C. H. Lai, MB ChB, MRCSEd, FRACS

Published in: Annals of Surgical Oncology | Issue 12/2007

Login to get access

Abstract

Background

Surgical resection with complete extirpation of the tumor gives the best chance of a cure for patients with hepatocellular carcinoma (HCC). However, the resectability of HCC at the time of diagnosis is low (10–30%). This article reviews the use of salvage surgery following tumor downstaging to treat unresectable HCC.

Materials and Methods

A Medline search was undertaken from 1966 to 2005 to identify articles using the keywords “liver neoplasm,” “hepatocellular carcinoma,” “tumor downstaging,” and “unresectable.” Additional papers were identified by a manual search of the references from the key articles.

Results

Eight to eighteen percent of patients with unresectable HCC responded well enough to the initial palliative treatment to downstage HCC to allow salvage surgical resection. The reported five-year survival rate after salvage surgery following tumor downstaging varied from 24.9 to 57%.

Conclusions

Although it is still unknown whether the outcome of salvage surgery following tumor downstaging is comparable to those of resectable tumors after primary resection, one clear message is that salvage surgery following tumor downstaging gives good long-term results and the possibility of a cure in a proportion of patients with unresectable HCC. The role of salvage surgery after tumor downstaging in improving disease-free and overall survival in patients with unresectable HCC should be investigated further by prospective randomized controlled trials.
Literature
1.
go back to reference Lau WY. Primary hepatocellular carcinoma. In: Blumgart LH, Fong Y, (eds.) Surgery of the Liver and Biliary Tract. 3rd ed. London: WB Saunders, 2000:1423–50 Lau WY. Primary hepatocellular carcinoma. In: Blumgart LH, Fong Y, (eds.) Surgery of the Liver and Biliary Tract. 3rd ed. London: WB Saunders, 2000:1423–50
2.
go back to reference Lau WY. Management of hepatocellular carcinoma. J R Coll Surg Edinb 2002;47:389–99PubMed Lau WY. Management of hepatocellular carcinoma. J R Coll Surg Edinb 2002;47:389–99PubMed
4.
5.
go back to reference Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421–7PubMedCrossRef Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421–7PubMedCrossRef
6.
go back to reference Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676–81PubMed Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676–81PubMed
7.
go back to reference Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004;40:1474–84PubMedCrossRef Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004;40:1474–84PubMedCrossRef
8.
go back to reference Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429–42PubMedCrossRef Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429–42PubMedCrossRef
9.
go back to reference Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90 yttrium microspheres. Int J Radiat Oncol Bio Phys 1998;40:583–92CrossRef Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90 yttrium microspheres. Int J Radiat Oncol Bio Phys 1998;40:583–92CrossRef
10.
go back to reference Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001; 233:236–41PubMedCrossRef Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001; 233:236–41PubMedCrossRef
11.
go back to reference Lau WY. Cure is possible with salvage surgery following downstaging of hepatocellular carcinoma. Chinese-Ger J Clin Oncol 2004;3:130–1 Lau WY. Cure is possible with salvage surgery following downstaging of hepatocellular carcinoma. Chinese-Ger J Clin Oncol 2004;3:130–1
13.
go back to reference Pierro A, Langevin AM, Filler RM, et al. Preoperative chemotherapy in ‘unresectable’ hepatoblastoma. J Pediatr Surg 1989;24:24–8PubMedCrossRef Pierro A, Langevin AM, Filler RM, et al. Preoperative chemotherapy in ‘unresectable’ hepatoblastoma. J Pediatr Surg 1989;24:24–8PubMedCrossRef
14.
go back to reference Reynolds M. Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study. World J Surg 1995;19:814–6PubMedCrossRef Reynolds M. Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study. World J Surg 1995;19:814–6PubMedCrossRef
15.
go back to reference Stringer MD, Hennayake S, Howard ER, et al. Improved outcome for children with hepatoblastoma. Br J Surg 1995;82:386–91PubMedCrossRef Stringer MD, Hennayake S, Howard ER, et al. Improved outcome for children with hepatoblastoma. Br J Surg 1995;82:386–91PubMedCrossRef
16.
go back to reference Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer 2002;94:1111–20PubMedCrossRef Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer 2002;94:1111–20PubMedCrossRef
17.
go back to reference Perilongo G, Brown J, Shafford E, et al. Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors. Cancer 2000;89:1845–53PubMedCrossRef Perilongo G, Brown J, Shafford E, et al. Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors. Cancer 2000;89:1845–53PubMedCrossRef
18.
go back to reference Perilongo G, Shafford E, Maibach R, et al. International Society of Paediatric Oncology-SIOPEL 2. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology–SIOPEL 2. Eur J Cancer 2004;40:411–21PubMedCrossRef Perilongo G, Shafford E, Maibach R, et al. International Society of Paediatric Oncology-SIOPEL 2. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology–SIOPEL 2. Eur J Cancer 2004;40:411–21PubMedCrossRef
19.
go back to reference Fuchs J, Rydzynski J, Hecker H, et al. German Cooperative Liver Tumor Studies HB 89 and HB 94. The influence of preoperative chemotherapy and surgical technique in the treatment of hepatoblastoma–a report from the German Cooperative Liver Tumor Studies HB 89 and HB 94. Eur J Pediatr Surg 2002;12:255–61PubMedCrossRef Fuchs J, Rydzynski J, Hecker H, et al. German Cooperative Liver Tumor Studies HB 89 and HB 94. The influence of preoperative chemotherapy and surgical technique in the treatment of hepatoblastoma–a report from the German Cooperative Liver Tumor Studies HB 89 and HB 94. Eur J Pediatr Surg 2002;12:255–61PubMedCrossRef
20.
go back to reference Fuchs J, Rydzynski J, von Schweinitz D, et al. Study Committee of the Cooperative Pediatric Liver Tumor Study HB 94 for the German Society for Pediatric Oncology and Hematology. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002;95:172–82PubMedCrossRef Fuchs J, Rydzynski J, von Schweinitz D, et al. Study Committee of the Cooperative Pediatric Liver Tumor Study HB 94 for the German Society for Pediatric Oncology and Hematology. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002;95:172–82PubMedCrossRef
21.
go back to reference von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumor Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer 1997;33:1243–9CrossRef von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumor Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer 1997;33:1243–9CrossRef
22.
go back to reference Fusai G, Davidson BR. Strategies to increase the resectability of liver metastases from colorectal cancer. Dig Surg 2003;20:481–96PubMedCrossRef Fusai G, Davidson BR. Strategies to increase the resectability of liver metastases from colorectal cancer. Dig Surg 2003;20:481–96PubMedCrossRef
23.
24.
go back to reference Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509–20PubMedCrossRef Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509–20PubMedCrossRef
25.
go back to reference Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933–9PubMedCrossRef Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933–9PubMedCrossRef
26.
go back to reference Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644–57PubMedCrossRef Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644–57PubMedCrossRef
27.
go back to reference Stocker JT, Ishak KG. Undifferentiated (embryonal) sarcoma of the liver: report of 31 cases. Cancer 1978;42:336–48PubMedCrossRef Stocker JT, Ishak KG. Undifferentiated (embryonal) sarcoma of the liver: report of 31 cases. Cancer 1978;42:336–48PubMedCrossRef
28.
go back to reference Horowitz ME, Etcubanas E, Webber BL, et al. Hepatic undifferentiated (embryonal) sarcoma and rhabdomyosarcoma in children. Results of therapy. Cancer 1987;59:396–402PubMedCrossRef Horowitz ME, Etcubanas E, Webber BL, et al. Hepatic undifferentiated (embryonal) sarcoma and rhabdomyosarcoma in children. Results of therapy. Cancer 1987;59:396–402PubMedCrossRef
29.
go back to reference Urban CE, Mache CJ, Schwinger W, et al. Undifferentiated (embryonal) sarcoma of the liver in childhood. Successful combined-modality therapy in four patients. Cancer 1993;72:2511–6PubMedCrossRef Urban CE, Mache CJ, Schwinger W, et al. Undifferentiated (embryonal) sarcoma of the liver in childhood. Successful combined-modality therapy in four patients. Cancer 1993;72:2511–6PubMedCrossRef
30.
go back to reference Bisogno G, Pilz T, Perilongo G, et al. Undifferentiated sarcoma of the liver in childhood: a curable disease. Cancer 2002;94:252–7PubMedCrossRef Bisogno G, Pilz T, Perilongo G, et al. Undifferentiated sarcoma of the liver in childhood: a curable disease. Cancer 2002;94:252–7PubMedCrossRef
31.
go back to reference Kim DY, Kim KH, Jung SE, et al. Undifferentiated (embryonal) sarcoma of the liver: combination treatment by surgery and chemotherapy. J Pediatr Surg 2002;37:1419–23PubMedCrossRef Kim DY, Kim KH, Jung SE, et al. Undifferentiated (embryonal) sarcoma of the liver: combination treatment by surgery and chemotherapy. J Pediatr Surg 2002;37:1419–23PubMedCrossRef
32.
go back to reference Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610–30PubMed Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610–30PubMed
33.
go back to reference Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–66PubMedCrossRef Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–66PubMedCrossRef
34.
go back to reference Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–18PubMedCrossRef Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–18PubMedCrossRef
35.
go back to reference Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59–71PubMedCrossRef Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59–71PubMedCrossRef
36.
37.
go back to reference Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136–47PubMed Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136–47PubMed
38.
go back to reference de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47PubMed de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47PubMed
39.
go back to reference Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–14CrossRef Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–14CrossRef
40.
go back to reference Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicener randomised trial. Lancet 2000;355:1041–7PubMedCrossRef Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicener randomised trial. Lancet 2000;355:1041–7PubMedCrossRef
41.
go back to reference Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 1998;15:674–8PubMedCrossRef Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 1998;15:674–8PubMedCrossRef
42.
go back to reference Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226:688–701PubMedCrossRef Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226:688–701PubMedCrossRef
43.
go back to reference Tang ZY, Zhou XD, Ma ZC, et al. Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004;3:495–8PubMed Tang ZY, Zhou XD, Ma ZC, et al. Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004;3:495–8PubMed
44.
go back to reference Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004;240:299–305PubMedCrossRef Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004;240:299–305PubMedCrossRef
45.
go back to reference Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg 1993; 217:149–54PubMed Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg 1993; 217:149–54PubMed
46.
go back to reference Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000;7:490–5PubMedCrossRef Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000;7:490–5PubMedCrossRef
47.
go back to reference Clavien PA, Selzner N, Morse M, et al. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002;131:433–42PubMedCrossRef Clavien PA, Selzner N, Morse M, et al. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002;131:433–42PubMedCrossRef
48.
go back to reference Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532–8PubMedCrossRef Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532–8PubMedCrossRef
Metadata
Title
Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma—A Strategy to Increase Resectability
Authors
Wan Yee Lau, MD, FACS, FRCS, FRACS(Hon)
Eric C. H. Lai, MB ChB, MRCSEd, FRACS
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9549-7

Other articles of this Issue 12/2007

Annals of Surgical Oncology 12/2007 Go to the issue